findmyKOL
Clinical trialNCT01851551CompletedPhase 1/PHASE2Interventional

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

SponsorAcrotech Biopharma Inc.Enrollment22Diffuse Large B-cell LymphomaMantle Cell LymphomaNon-Hodgkin's Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a single arm, open label study evaluating VSLI plus rituximab in adults with aggressive relapsed or refractory non-Hodgkin's lymphoma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom
  • Leeds General Infirmary

    Leeds, West Yorkshire, United Kingdom

United States
  • University of California

    San Francisco, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Vincristine Sulfate Liposome Injection plus rituximab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2001
Primary completion
30 Apr 2004
Completion
30 Apr 2005
Last update posted
3 Jan 2020
Registered enrollment
22
Registry id
NCT01851551
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.